Based on the positive results of preclinical studies showing that TLR9 activation can induce adjuvant effects to promote T-cell activation and reduce tumor burden, CpG-ODNs have been investigated in clinical trials as therapeutic antitumor agents (10, 35, 137, 138). Here, TLR9 is linked to neoplasm.